Genomic technologies, once confined to research labs, are now readily available to consumers, promising insights into health risks and ancestry. However, experts urge caution, highlighting significant limitations and potential societal consequences.
Researchers Daphne Martschenko and Sam Trejo emphasize that many direct-to-consumer (DTC) genetic tests overstate the predictive power of DNA, often promoting a "destiny myth." This misconception suggests genetic predispositions are immutable, ignoring the complex interplay of social and environmental factors. While scientific advancements have improved the ability to analyze genomes and predict traits, the underlying mechanisms connecting DNA to life outcomes remain poorly understood.
Daphne Martschenko, assistant professor of biomedical ethics at Stanford University, noted that polygenic scores, used in embryo selection and DTC testing, often function as "black box predictors." The accuracy of these scores can be close to zero for many traits, especially outside of specific diseases like Huntington's or cystic fibrosis. Furthermore, these scores are often trained on datasets predominantly from European ancestry, leading to significantly reduced accuracy for individuals of other backgrounds.
Sam Trejo, assistant professor of sociology at Princeton University, pointed out the lack of transparency from companies regarding their data sources and analytical methods. He stated that for most traits, thousands of genetic variants are involved, yet DTC tests may focus on only a few, leading to misleading conclusions about risk.
While polygenic scores show potential for medical applications, such as stratifying risk for conditions like heart disease or type 2 diabetes, their use in areas like embryo selection for intelligence or admissions processes raises ethical concerns. The historical misuse of genetic claims to justify social harm, such as race-based discrimination and involuntary sterilization, underscores the need for careful consideration.
The experts advocate for greater regulation of genetic technologies and call for public education on the limitations of DTC tests and polygenic scores, enabling consumers to make informed decisions.